A huge task awaits the future executive director of the European Medicines Agency (EMA) when current executive Guido Rasi steps down in the end of 2020. His successor should be an experienced diplomat and not on any account a visionless administrator, says director of the Danish Medicines Agency.
Novo Nordisk expands the workforce to develop of digital products such as insulin pens registering doses in an app. The goal is to beat the competition from Eli Lilly and Sanofi.
Paul Marcun, Executive Officer of Coloplast's lucrative chronic care division, has one goal: Growth. For that purpose, he wants to upgrade the Chinese market and close a deal with US procurement organization.
Roche Diagnostics Denmark has signed a partnership agreement with innovation center Nordic Health Lab at New North Zealand Hospital. The parties want to kick off development of solutions for early identification and disease prevention.
After a turbulent year, new Ambu CEO Juan-José Gonzalez has cleaned up in the company and set new standards, says Danske Bank analyst. Investment managers and hedge funds reduce their short positions.
Danish healthtech firm Radiobotics has received DKK 2.1 million from Innovation Fund Denmark to expand the team and launch its product in Europe next year. The US is up next, and the company anticipates an annual revenue of DKK 200 million in five years.
A group of investors who demand DKK 11.8 billion in compensation from Novo Nordisk plans to summon 19 former and current Novo executives and a whistleblower as witnesses in the case.
.jpg)
64 persons want to succeed Executive Director of the European Medicines Agency (EMA) Guido Rasi when he steps down next year.
.jpg)
It was Peter Buhl Jensen's own choice to resign as CEO of Oncology Venture and cede control to American Steve Carchedi. According to Buhl himself, he is not the right man to take his company to the next phase.
After more than 10 years as CEO of Rhovac, Anders Ljungqvist steps down with immediate effect. His successor is Leo Pharma's former Head of Global Business Development.
Danish Søren Bregenholt is heading for a busy career as CEO of UK-based Macrophage Pharma where he is to take the main asset to clinical development, raise more capital and attract partners from big pharma.
.jpg)
During the past 10 years, export rates have doubled for Danish life science, and medicines export increased twice as much as in he rest of Europe in the second quarter of 2019 alone. The Danish Minister for Finance is pleased, and industry association emphasizes the regulatory framework's importance for continued growth.
Danish Zealand Pharma can look forward to a three-digit million milestone payment after German partner Boehringer Ingelheim takes one of the drugs in-licensed from Zealand to next development phase. The Danish biotech firm now awaits Boehringer's decision regarding second candidate in the license agreement.
Danish Virogates has signed a deal with large French university hospital. CEO Jakob Knudsen calls it the company's largest customer and expects the collaboration to open more doors on the French market.
Senior Partner in Novo Seeds Stephan Christgau establishes new life science venture fund. The name and the three partners remain a secret, but the investor aims to be ready to put up to EUR 100 million into the life science industry this year.
Almost two years after taking position in Samplix, CEO Lars Kongsbak is ready to launch the company's first product. He is also looking for funds to finance, among other things, a US division.
The affluent Danish Schrøder family has increased its owner's share in Mequ, the company behind a transportable blood warmer. The medtech firm now prepares to enter the US market, which could be even more lucrative than anticipated.
Neither Vaccibody nor Martin Bonde himself wants to elaborate on why he steps down as CEO. But he was not fired, says the chairman of the board.
An engaged effort from the management brought the experienced Canadian researcher Eva Chin to a small Danish biotech firm. She left California with her family to move to Aarhus, the home of NMD Pharma, but the process has not been entirely smooth.
Danish medtech firm Robofit is in the middle of a patent dispute with University of Southern Denmark that could make the company go bankrupt in a few months. The start-up feels deceived by the university, and SDU calls the situation "aggravating."
This week, two new blood test laboratories opened at the hospitals in Herlev and Gentofte outside Copenhagen. For the provider, Siemens, the new labs mean closer ties to the Capital Region and increased presence in the Danish laboratory field.
The owner of Danish laboratory equipment provider Holm & Halby has acquired more Danish companis. Holm & Halby hopes that the new sister companies will help consolidate its position as supplier to the pharma industry.
Coloplast's Payers & Trade organization uses rhetoric, evidence and lobbyism to maintain the company's income. The organization recently cushioned the effect of a price reform in France and will play a key role in the future launch of digital ostomy bags.
.jpg)
The interest in partnering with 2curex is there, says CEO Ole Thastrup, adding that partnerships are an option when the company initiates the second round of market launches.
Zealand Pharma CEO Emmanuel Dulac has yet to find a new CSO and CFO for the company. He expects to appoint a candidate within few weeks – although he said so as early as May.
